EFPIA, Medicines for Europe and AESGP call for a Mutual Recognition Agreement on Good Manufacturing Practice in the context of EU-UK Future Relationship
In the coming months, the EU and UK should conclude an agreement that secures the greatest regulatory alignment and cooperation on human medicinal products. Reflecting precedents from previous agreements, an FTA should also include ambitious provisions on sharing of data, the protection of intellectual property (IP), customs facilitation, as well as rules of origin (RoO). We also believe the EU and UK should establish a working group on pharmaceuticals and medical devices as per the EU-South Korea Free Trade Agreement.
Given the current complete alignment of regulatory standards, the EU-UK negotiations represent a unique opportunity to continue this high level of compatibility and to secure streamlined processes and procedures between the EU and the UK in the interest of patients.
Read here the full call for a EU-UK Mutual Recognition Agreement on Good Manufacturing Practice.